44 expert articles exploring how AI, GenAI and Machine Learning are transforming Pharma, Diagnostics and Healthcare.
78% of executives lack confidence they could pass an independent AI governance audit within 90 days. What this proof gap means for boards, CFOs and CIOs, and how to close it.
81% of surveyed CISOs worry about AI agents running with access no one reviews, yet only 47% can identify every agent. A practical way to bring agent access under control.
68% of surveyed CISOs have detected unsanctioned AI use by staff. What shadow AI puts at risk, including trade secret protection, and how to replace bans with safe, approved paths.
CEOs worry most about the pace of AI transformation, and 56% report no significant financial benefit yet. How a risk-tiered fast track lets the business move faster while the guardrails stay in place.
Insurers are adding AI exclusions and narrowing cover, often quietly. What CFOs, general counsel and risk leaders should check before the next renewal.
51% of surveyed Swiss companies call Swiss or EU data protection compliance business-critical. A tiered way to decide which AI workloads need a sovereign path, and which do not.
A data-grounded framework for how Pharma CIOs and CDIOs should allocate AI budget this cycle, informed by Deloitte, ZS, McKinsey, and Benchling research on where pharma AI investment actually pays off.
How pharma, diagnostics and healthcare organisations in Switzerland and the EU can capture real AI value — with the right strategy, delivery framework and change management approach.
How AI-driven synthetic data generation and digital twin modeling are transforming clinical trial design, patient simulation, and drug development.
How AI is revolutionizing pharma IT service desks — from reactive ticket processing to proactive, intelligent IT support that understands GxP context.
How AI transforms L1/L2 support efficiency through intelligent knowledge retrieval, automated resolution suggestions, and self-learning knowledge bases for pharmaceutical IT operations.
How ML models are accelerating the identification of novel therapeutic targets in solid tumors.
How generative AI enables hyper-personalized content for healthcare professional outreach at scale.
Intelligent ticket routing, predictive incident management, and automated compliance documentation in pharma IT.
How to develop a pragmatic, value-driven AI strategy that aligns with pharma business priorities and regulatory realities.
How structured IT delivery management ensures large-scale pharma transformation programs stay on track, on budget, and compliant.
What makes project management in pharma IT different — and how to get it right for GxP and non-GxP initiatives.
Orchestrating multi-project transformation programs that deliver strategic outcomes, not just project outputs.
How pharma companies are adopting Agile and SAFe while maintaining GxP compliance — lessons from real transformations.
Generative AI is transforming how sponsors design adaptive clinical trial protocols — reducing timelines and costly amendments.
ML models forecasting payer decisions and optimizing pricing strategies across fragmented EU markets.
ML-driven data harmonization across disparate Life Sciences IT systems for a single source of truth.
Establishing AI governance frameworks that satisfy regulators while enabling innovation in pharma.
AI-assisted planning and risk assessment for migrating GxP-validated systems to the cloud.
Combining traditional PM rigor with agile flexibility — tailored for GxP-regulated systems delivery.
Governance structures that enable fast decisions while maintaining accountability and compliance.
Practical patterns for running agile sprints on GxP-regulated systems without sacrificing speed or compliance.
Using ML to identify predictive and prognostic biomarkers from multi-omics datasets for companion diagnostics.
Adapting GAMP 5 and CSV practices for AI/ML systems in regulated Life Sciences environments.
How AI is transforming the diagnostics industry — from laboratory-based companion diagnostics to real-time digital health monitoring.
Managing complex multi-vendor ecosystems in pharmaceutical IT programs without losing accountability or velocity.
How AI and next-best-action models help pharma commercial teams orchestrate rep visits, email, and digital HCP engagement.
How AI-driven analysis of configurations, dependencies, and validation records is reshaping risk-based cloud migration planning for GxP systems.
How physics-informed AI and ML surrogate models are reshaping lead optimization, binding affinity prediction, and ADMET screening in drug discovery.
How NLP turns ClinicalTrials.gov, publications, and regulatory filings into real-time competitive intelligence for pharma launch teams.
How AI-enhanced RPA handles exceptions in pharma invoicing, deviations, and batch review, and how ANG delivers these programs under GxP.
How validated NLP pipelines turn unstructured EHR notes into regulatory-grade real-world evidence, and what compliant implementation requires.
How generative AI can draft compliant medical information responses to HCPs, with label-anchored guardrails, human review, and real adoption data.
How AI-based threat detection helps pharma protect R&D data, clinical systems, and OT infrastructure while meeting NIS2 and Swiss rules.
How federated learning lets hospitals and research sites train AI models jointly without moving patient data, addressing GDPR and Swiss nDSG constraints.
How sequence models and clustering on claims, EMR, and patient-reported data reveal diagnostic delays and referral gaps in rare disease.
How deep learning models read whole-slide histopathology images, the regulatory pathways behind them, and what compliant deployment requires.
How AI dashboards help pharma key account managers unify formulary, stakeholder, and contract data for hospital and payer accounts.
New 2025-2026 survey data shows most pharma AI pilots stall before they scale. Three priorities leaders should act on now.